Skandinaviska Enskilda Banken AB publ Buys 190,255 Shares of Abbott Laboratories $ABT

Skandinaviska Enskilda Banken AB publ increased its stake in Abbott Laboratories (NYSE:ABT) by 51.6% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 559,321 shares of the healthcare product maker’s stock after purchasing an additional 190,255 shares during the period. Skandinaviska Enskilda Banken AB publ’s holdings in Abbott Laboratories were worth $74,915,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in ABT. IMG Wealth Management Inc. lifted its stake in shares of Abbott Laboratories by 759.1% during the second quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker’s stock valued at $26,000 after acquiring an additional 167 shares during the period. Cloud Capital Management LLC bought a new stake in shares of Abbott Laboratories during the third quarter worth approximately $29,000. Guerra Advisors Inc acquired a new position in Abbott Laboratories in the third quarter valued at approximately $31,000. Anfield Capital Management LLC boosted its stake in Abbott Laboratories by 81.3% in the second quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock valued at $32,000 after acquiring an additional 104 shares during the last quarter. Finally, Delos Wealth Advisors LLC acquired a new stake in Abbott Laboratories during the 2nd quarter worth $32,000. 75.18% of the stock is owned by institutional investors and hedge funds.

Abbott Laboratories Stock Performance

Shares of ABT stock opened at $112.63 on Tuesday. Abbott Laboratories has a 12 month low of $105.27 and a 12 month high of $141.23. The company’s fifty day simple moving average is $119.30 and its 200-day simple moving average is $126.29. The firm has a market cap of $195.84 billion, a PE ratio of 30.28, a P/E/G ratio of 1.79 and a beta of 0.75. The company has a quick ratio of 1.24, a current ratio of 1.70 and a debt-to-equity ratio of 0.23.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.50. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.94%. The firm had revenue of $11.46 billion for the quarter, compared to analyst estimates of $11.80 billion. During the same period in the previous year, the business earned $1.34 EPS. The company’s revenue was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Equities research analysts expect that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, February 13th. Investors of record on Thursday, January 15th were given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 2.2%. This is a boost from Abbott Laboratories’s previous quarterly dividend of $0.59. The ex-dividend date of this dividend was Thursday, January 15th. Abbott Laboratories’s payout ratio is currently 67.74%.

Insiders Place Their Bets

In related news, Director Daniel J. Starks acquired 10,000 shares of the business’s stock in a transaction on Wednesday, February 4th. The stock was purchased at an average cost of $108.73 per share, for a total transaction of $1,087,300.00. Following the completion of the transaction, the director directly owned 6,738,817 shares of the company’s stock, valued at approximately $732,711,572.41. The trade was a 0.15% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.46% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several equities analysts have weighed in on ABT shares. Argus cut their target price on Abbott Laboratories from $150.00 to $140.00 in a research note on Tuesday, January 27th. Sanford C. Bernstein cut their price target on shares of Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating on the stock in a research report on Friday, January 23rd. Leerink Partners reduced their price objective on shares of Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating on the stock in a research note on Friday, January 30th. Evercore lowered their target price on shares of Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating for the company in a research note on Friday, January 23rd. Finally, Daiwa Securities Group reduced their price target on shares of Abbott Laboratories from $136.00 to $113.00 and set an “outperform” rating on the stock in a research report on Friday, January 30th. Two analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Abbott Laboratories presently has an average rating of “Moderate Buy” and a consensus price target of $137.05.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.